Biomarin Pharmaceutical (BMRN) Current Assets (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Current Assets data on file, last reported at $4.6 billion in Q1 2026.

• Quarterly Current Assets rose 32.79% year-over-year to $4.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 billion (up 32.79% YoY) and the FY2025 annual result came in at $4.0 billion, up 22.31% from the prior year.
• Current Assets advanced to $4.6 billion in Q1 2026, from $4.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $4.6 billion in Q1 2026 to a low of $2.4 billion in Q1 2022.
• A 5-year average of $3.2 billion and a median of $3.0 billion in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets rose 3.43% — and 2026, when it surged 32.79%.
• Tracing BMRN's Current Assets over 5 years: stood at $2.8 billion in 2022, then grew by 7.44% to $3.0 billion in 2023, then increased by 9.35% to $3.2 billion in 2024, then rose by 22.31% to $4.0 billion in 2025, then increased by 16.48% to $4.6 billion in 2026.
• The last three Current Assets figures came in at $4.6 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.9 billion (Q3 2025), per Business Quant data.